Pyxis Oncology Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Lara Sullivan
Chief executive officer
US$4.4m
Total compensation
| CEO salary percentage | 14.1% |
| CEO tenure | 5yrs |
| CEO ownership | 3.1% |
| Management average tenure | 2.9yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead
Dec 07Moment Of Truth Approaches For Pyxis Oncology
Sep 13Pyxis Oncology: Promising Research Amid Cash Constraints
Jun 10Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
Mar 28Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis
Jan 18Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
Feb 18
Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation
Sep 01Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06
Aug 15We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely
Apr 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$57m |
| Jun 30 2024 | n/a | n/a | -US$59m |
| Mar 31 2024 | n/a | n/a | -US$58m |
| Dec 31 2023 | US$4m | US$625k | -US$74m |
| Sep 30 2023 | n/a | n/a | -US$94m |
| Jun 30 2023 | n/a | n/a | -US$99m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$5m | US$565k | -US$121m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$88m |
| Mar 31 2022 | n/a | n/a | -US$71m |
| Dec 31 2021 | US$17m | US$565k | -US$76m |
| Sep 30 2021 | n/a | n/a | -US$64m |
| Jun 30 2021 | n/a | n/a | -US$53m |
| Mar 31 2021 | n/a | n/a | -US$47m |
| Dec 31 2020 | US$555k | US$375k | -US$13m |
Compensation vs Market: Lara's total compensation ($USD4.44M) is above average for companies of similar size in the US market ($USD653.16K).
Compensation vs Earnings: Lara's compensation has been consistent with company performance over the past year.
CEO
Lara Sullivan
5yrs
Tenure
US$4,442,501
Compensation
Dr. Lara S. Sullivan, M.D., MBA, has been Chief Executive Officer, President and Director at Pyxis Oncology, Inc. since December 2019. She was a Principal at Paul Capital Partners, since April 2007. Dr. Su...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5yrs | US$4.44m | 3.14% $ 3.2m | |
| CFO & COO | 3.4yrs | US$1.82m | 1.26% $ 1.3m | |
| Chief Medical Officer | 1.1yrs | US$1.13m | no data | |
| Chief Accounting Officer | 3.3yrs | no data | 0.26% $ 261.9k | |
| Interim Chief Technology Officer | 2.9yrs | no data | no data | |
| Chief Scientific Officer | 2.7yrs | no data | no data | |
| Senior Vice President of Portfolio & Program Management | 2.9yrs | no data | no data | |
| Senior VP & Chief Business Officer | less than a year | no data | no data |
2.9yrs
Average Tenure
61.5yo
Average Age
Experienced Management: PYXS's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5yrs | US$4.44m | 3.14% $ 3.2m | |
| Independent Chairman | 5.6yrs | US$395.48k | 0.64% $ 638.5k | |
| Member of Clinical & Translational Medicine Advisory Board | 3.5yrs | no data | no data | |
| Independent Director | 3.3yrs | US$341.98k | 0.35% $ 348.5k | |
| Independent Director | 3.3yrs | US$357.48k | 0.36% $ 365.4k | |
| Independent Director | 3.3yrs | US$360.48k | 0.37% $ 375.0k | |
| Member of Clinical & Translational Medicine Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | 2.7yrs | no data | no data | |
| Chairperson of Technical Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | no data | no data | no data |
3.3yrs
Average Tenure
55yo
Average Age
Experienced Board: PYXS's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pyxis Oncology, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Tiago Fauth | Credit Suisse |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |